Aducanumab- a Drug of hope for the elderly
Madam, Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by impaired cognitive functions in a person (1). It is the most common cause of dementia and a major cause of morbidity and mortality in the elderly. Currently, 50 million people in the world live with dementi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pakistan Medical Association
2022-04-01
|
| Series: | Journal of the Pakistan Medical Association |
| Online Access: | https://www.ojs.jpma.org.pk/index.php/public_html/article/view/4418 |
| _version_ | 1797820795870773248 |
|---|---|
| author | Muhammad Kashan Zaheer Wajiha Siddiqi Ghana Raza |
| author_facet | Muhammad Kashan Zaheer Wajiha Siddiqi Ghana Raza |
| author_sort | Muhammad Kashan Zaheer |
| collection | DOAJ |
| description |
Madam, Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by impaired cognitive functions in a person (1). It is the most common cause of dementia and a major cause of morbidity and mortality in the elderly. Currently, 50 million people in the world live with dementia, AD accounting for more than half (50-75%) of all cases (2). Despite such an extensive burden of the disease, existing management options such as cholinesterase inhibitors and NMDA antagonists have failed to improve disease progress and are mainly focused on treating the symptoms.
Last month, on the 7th of June 2021 the U.S. Food and Drug Administration (FDA) approved Biogen® 's Aducanumab (ADU), an anti- beta-amyloid (A?) monoclonal antibody for the treatment of AD (3). Although controversial, the FDA’S approval of the drug marks a historic event in the fight against this debilitating disease. ADU represents the first of its kind treatment against AD. It is the only new Alzheimer’s drug to be approved in almost two decades and it’s also the first drug to target A?, a hallmark of AD pathophysiology. In a study, 3382 patients with AD were enrolled on three clinical trials to check for its efficacy. Patients who received the drug showed a time-dependent reduction of beta-amyloid plaque, while on the contrary, those on placebo did not. (4) However, due to inconsistent results in the phase III trials (5), FDA requires Biogen to conduct a post-approval trial to verify clinical benefit. Failing to do so, may result in the FDA withdrawing the approval. Despite limited evidence regarding its efficacy, annual ADU therapy is priced at U$D56000, raising healthcare equity, accessibility, and affordability concerns.
Presently 60% of the world’s population living with dementia belongs to low-middle income countries, by 2050 this number shall expectedly rise to 71%. Along with its South Asian and Western Pacific neighbors, Pakistan comprises the world’s fastest-growing elderly population (6), which ultimately means more people with AD. This means we require efficient therapy options to fight an ever-growing disease burden in the upcoming years. Therefore, it is pivotal to acknowledge that ADU the first therapy to halt AD progression, is a milestone achieved in its treatment. It should be considered as a step forward towards the path to finding a cure.
|
| first_indexed | 2024-03-13T09:44:35Z |
| format | Article |
| id | doaj.art-87229e74c3234297a8a7153e8984d9f5 |
| institution | Directory Open Access Journal |
| issn | 0030-9982 |
| language | English |
| last_indexed | 2024-03-13T09:44:35Z |
| publishDate | 2022-04-01 |
| publisher | Pakistan Medical Association |
| record_format | Article |
| series | Journal of the Pakistan Medical Association |
| spelling | doaj.art-87229e74c3234297a8a7153e8984d9f52023-05-25T04:22:26ZengPakistan Medical AssociationJournal of the Pakistan Medical Association0030-99822022-04-0172210.47391/JPMA.4418Aducanumab- a Drug of hope for the elderlyMuhammad Kashan Zaheer0Wajiha Siddiqi1Ghana Raza2Final Year MBBS Student, Liaquat National Hospital and Medical College, Karachi, PakistanFinal Year MBBS Student, Liaquat National Hospital and Medical College, Karachi, PakistanSecond Year MBBS Student, Jinnah Sindh Medical University, Karachi, Pakistan Madam, Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by impaired cognitive functions in a person (1). It is the most common cause of dementia and a major cause of morbidity and mortality in the elderly. Currently, 50 million people in the world live with dementia, AD accounting for more than half (50-75%) of all cases (2). Despite such an extensive burden of the disease, existing management options such as cholinesterase inhibitors and NMDA antagonists have failed to improve disease progress and are mainly focused on treating the symptoms. Last month, on the 7th of June 2021 the U.S. Food and Drug Administration (FDA) approved Biogen® 's Aducanumab (ADU), an anti- beta-amyloid (A?) monoclonal antibody for the treatment of AD (3). Although controversial, the FDA’S approval of the drug marks a historic event in the fight against this debilitating disease. ADU represents the first of its kind treatment against AD. It is the only new Alzheimer’s drug to be approved in almost two decades and it’s also the first drug to target A?, a hallmark of AD pathophysiology. In a study, 3382 patients with AD were enrolled on three clinical trials to check for its efficacy. Patients who received the drug showed a time-dependent reduction of beta-amyloid plaque, while on the contrary, those on placebo did not. (4) However, due to inconsistent results in the phase III trials (5), FDA requires Biogen to conduct a post-approval trial to verify clinical benefit. Failing to do so, may result in the FDA withdrawing the approval. Despite limited evidence regarding its efficacy, annual ADU therapy is priced at U$D56000, raising healthcare equity, accessibility, and affordability concerns. Presently 60% of the world’s population living with dementia belongs to low-middle income countries, by 2050 this number shall expectedly rise to 71%. Along with its South Asian and Western Pacific neighbors, Pakistan comprises the world’s fastest-growing elderly population (6), which ultimately means more people with AD. This means we require efficient therapy options to fight an ever-growing disease burden in the upcoming years. Therefore, it is pivotal to acknowledge that ADU the first therapy to halt AD progression, is a milestone achieved in its treatment. It should be considered as a step forward towards the path to finding a cure. https://www.ojs.jpma.org.pk/index.php/public_html/article/view/4418 |
| spellingShingle | Muhammad Kashan Zaheer Wajiha Siddiqi Ghana Raza Aducanumab- a Drug of hope for the elderly Journal of the Pakistan Medical Association |
| title | Aducanumab- a Drug of hope for the elderly |
| title_full | Aducanumab- a Drug of hope for the elderly |
| title_fullStr | Aducanumab- a Drug of hope for the elderly |
| title_full_unstemmed | Aducanumab- a Drug of hope for the elderly |
| title_short | Aducanumab- a Drug of hope for the elderly |
| title_sort | aducanumab a drug of hope for the elderly |
| url | https://www.ojs.jpma.org.pk/index.php/public_html/article/view/4418 |
| work_keys_str_mv | AT muhammadkashanzaheer aducanumabadrugofhopefortheelderly AT wajihasiddiqi aducanumabadrugofhopefortheelderly AT ghanaraza aducanumabadrugofhopefortheelderly |